Grades, scores, and FDA catalyst signals for Gene Editing stocks tracked by BiotechSigns
| Ticker | Company | Score | Grade | Sector | Signals |
|---|---|---|---|---|---|
| EDIT | Editas Medicine | 54 | C | Gene Editing | — |
Gene editing companies use CRISPR/Cas9, base editing, prime editing, or zinc-finger nuclease (ZFN) technology to make precise, permanent modifications to a patient's DNA. The first CRISPR therapy (Casgevy) received FDA approval in late 2023, marking a watershed moment for the field. High capital requirements, complex ex vivo and in vivo manufacturing, and long development timelines create elevated dilution risk. FDA has been thoughtful in establishing regulatory precedent for these novel modalities, and each new approval clarifies the path for subsequent entrants. PDUFA dates for gene editing therapies are rare but high-impact binary events that attract significant institutional attention.